Veracyte annonce que le test Decipher Prostate identifie les patients tirant profit d'une chimiothérapie dans le cancer de la prostate métastatique

une approche dite de 'triplette' - et ceux qui peuvent l'eviter en toute sécurité. Ces données constituent la première preuve de niveau 1B pour un test génomique guidant cette décision.
Standard-Journal

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate ...
Zonebourse

Une nouvelle étude révèle que le test Decipher Prostate prédit le bénéfice de la chimiothérapie chez les patients atteints d'un cancer de la prostate métastatique

Veracyte, Inc. et l'University College London (UCL) ont annoncé la publication en ligne, dans la revue Cell, de données démontrant que le test génomique Decipher Prostate permet de prédire quels ...
The Globe and Mail

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

“Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the growing population of patients with metastatic prostate cancer,” said ...
Medical Xpress

Molecular test helps tailor chemotherapy for advanced prostate cancer patients

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
01Net

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN ...
EurekAlert!

Molecular test personalizes prostate cancer treatment

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Nasdaq

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...